Date: 2013-02-20
Type of information:
Compound:
Company: Selexis (Switzerland) Amgen (USA)
Therapeutic area:
Type agreement: licensing
R&D
Action mechanism:
Disease:
Details: * On February 20, 2013, Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, has announced that Amgen has expanded their R&D License Agreement with Selexis to include an evaluation of the proprietary Selexis SURE CHO-M Cell Line™ for research and development. Under the agreement, Amgen will be able to evaluate the SURE CHO-M Cell Line™ in conjunction with the Selexis SUREtech Vectors™ for improved R&D. “ This current agreement is built on the long-standing relationship between our two companies since 2004”said Igor Fisch, Ph.D., President and CEO of Selexis.
Financial terms:
Latest news:
